Titlebook: Hygrothermal Behaviour and Building Pathologies; J.M.P.Q. Delgado Book 2021 The Editor(s) (if applicable) and The Author(s), under exclusi

變更

書目名稱Hygrothermal Behaviour and Building Pathologies影響因子(影響力)




書目名稱Hygrothermal Behaviour and Building Pathologies影響因子(影響力)學(xué)科排名




書目名稱Hygrothermal Behaviour and Building Pathologies網(wǎng)絡(luò)公開度




書目名稱Hygrothermal Behaviour and Building Pathologies網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Hygrothermal Behaviour and Building Pathologies被引頻次




書目名稱Hygrothermal Behaviour and Building Pathologies被引頻次學(xué)科排名




書目名稱Hygrothermal Behaviour and Building Pathologies年度引用




書目名稱Hygrothermal Behaviour and Building Pathologies年度引用學(xué)科排名




書目名稱Hygrothermal Behaviour and Building Pathologies讀者反饋




書目名稱Hygrothermal Behaviour and Building Pathologies讀者反饋學(xué)科排名

aerial

ethnology

VALID

Mechanics

de the enamel in both mineralized and nonmineralized tissues. In bone, functional studies have demonstrated crucial functions of AMBN in the control of bone balance, notably processes associated with a high bone remodeling rate. In contrast to appendicular and axial bones, jaw bones are highly affec

flaggy

Sneha Das,Kaustav Sarkar, other regimens should not be withheld from women who cannot receive an anthracyline. Current clinical data also suggest a possible sensitivity to taxane-based therapy, especially when combined with an anthracycline. Trastuzumab-based therapy should be considered as first line therapy for women wit

愚蠢人

A. C. Azevedo,J. M. P. Q. Delgado,A. S. Guimar?es,I. Ribeiro,R. Sousa lung, or liver. Recent clinical studies involving more than 3000 breast cancer patients demonstrated that presence of tumor cells in bone marrow at primary diagnosis is an independent prognostic factor for unfavorable clinical outcome. To date, sampling of bone marrow, however, is not a routine pro

追逐

Debate

受辱

E. F. Felix,E. Possan,R. Carrazedoation studies is addressed for (1) identifying node-negative breast cancer patients who do not require systemic chemotherapy; (2) identifying node-positive breast cancer patients who do not benefit from standard chemotherapy; and (3) identifying node-positive breast cancer patients who benefit from